Gavin Clark-Gartner Analyst PerformanceManaging Director, Biotechnology Equity Research at EvercoreGavin Clark-Gartner is a stock analyst at Evercore focused in the medical sector, covering 13 publicly traded companies. Over the past year, Gavin Clark-Gartner has issued 18 stock ratings, including and buy recommendations. While full access to Gavin Clark-Gartner's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gavin Clark-Gartner's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings21 Last 1 YearsBuy Recommendations100.00% 20 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution20RatingsDistribution of strong buy, buy, hold, and sell ratings by Gavin Clark-Gartner.RatingPercentageCount Strong Buy0.0%0 ratings Buy100.0%20 ratings Hold0.0%0 ratings Sell0.0%0 ratingsthe majority (100.0%) have been Buy recommendations.Best & Worst CallsBest Call0000.0%DFTXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%PRQRApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ84.6% of companies on NASDAQ11 companiesNYSE15.4% of companies on NYSE2 companiesGavin Clark-Gartner, an analyst at Evercore, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical12 companies92.3%Manufacturing1 company7.7%Gavin Clark-Gartner of Evercore specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE9 companies69.2%LARGE CAP PHARMA1 company7.7%MED - DRUGS1 company7.7%Miscellaneous1 company7.7%BIOTECHNOLOGY1 company7.7% Gavin Clark-Gartner's Ratings History at Evercore Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMIRMMirum Pharmaceuticals3/4/2026Set Price Target$88.99$126.00$0.0000.00% ROIMIRMMirum Pharmaceuticals2/26/2026Reiterated Rating$92.71Outperform$0.0000.00% ROIABBVAbbVie2/4/2026Lower Price Target$218.89$228.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics1/20/2026Reiterated Rating$32.80$44.00Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals1/20/2026Reiterated Rating$91.05$101.00Outperform$0.0000.00% ROIDYNDyne Therapeutics12/15/2025Lower Price Target$19.27$36.00Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals12/8/2025Boost Price Target$67.90$94.00Outperform$0.0000.00% ROIVERAVera Therapeutics12/8/2025Boost Price Target$44.90$97.00Outperform$0.0000.00% ROIEVMNEvommune12/1/2025Initiated Coverage$20.71$40.00Outperform$0.0000.00% ROIFBRXForte Biosciences11/25/2025Initiated Coverage$19.06$65.00Outperform$0.0000.00% ROIDYNDyne Therapeutics11/6/2025Reiterated Rating$18.77$38.00Outperform$0.0000.00% ROIARGXargenex10/31/2025Boost Price Target$820.36$910.00Outperform$0.0000.00% ROIINSMInsmed10/1/2025Reiterated Rating$146.48$180.00Outperform$0.0000.00% ROIJSPRJasper Therapeutics9/22/2025Lower Price Target$2.49$14.00Outperform$0.0000.00% ROIABBVAbbVie9/22/2025Boost Price Target$224.25$222.00Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals8/8/2025Boost Price Target$59.82$89.00Outperform$0.0000.00% ROIRNAAvidity Biosciences7/11/2025Reiterated Rating$31.48$70.00Outperform$0.0000.00% ROIJSPRJasper Therapeutics7/8/2025Lower Price Target$3.04$20.00Outperform$0.0000.00% ROIPRQRProQR Therapeutics4/29/2025Initiated Coverage$1.54$5.00Outperform$0.0000.00% ROIABBVAbbVie4/28/2025Boost Price Target$188.39$205.00Outperform$000.0000.00% ROIDFTXDefinium Therapeutics1/28/2025Initiated Coverage$6.90$23.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenThe Goldman Sachs GroupBerenberg BankGuggenheimUBS GroupWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJefferies Financial GroupBTIG ResearchCanadian Imperial Bank of CommerceWeiss RatingsCitigroupBarclaysJPMorgan Chase & Co. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
